Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.
"acne inversa"
"hidradenitis suppurativa"
PAPA
PAPASH
PASH
PASS
SAPHO
arthritis
autoinflammatory
hidradenitis
pustulosis
secukinumab
syndrome
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2021
2021
Historique:
accepted:
14
06
2021
entrez:
21
9
2021
pubmed:
22
9
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Syndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic arthritis (PAPASH), spondyloarthritis (PASS) and psoriatic arthritis (PsAPASH) and are categorized in the autoinflammatory syndromes. Anti-TNF-α and anti-IL-1a blockade are between the therapeutic approaches that improve skin symptoms and prevent permanent osteoarticular damage. This case report refers to the successful treatment of a mixed phenotype of the aforementioned symptoms using the IL-17A inhibitor secukinumab after initial treatment with adalimumab. The therapy improved both cutaneous and reported osteoarticular symptoms. Different approaches for these recalcitrant HS syndromes are essential in order to achieve long-term remission for those patients.
Identifiants
pubmed: 34540202
doi: 10.12688/f1000research.52100.2
pmc: PMC8424462
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Interleukin-17
0
Tumor Necrosis Factor Inhibitors
0
secukinumab
DLG4EML025
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
381Informations de copyright
Copyright: © 2021 Nikolakis G et al.
Déclaration de conflit d'intérêts
No competing interests were disclosed.
Références
Eur J Immunol. 2010 May;40(5):1461-72
pubmed: 20162553
J Am Acad Dermatol. 2012 Mar;66(3):409-15
pubmed: 21745697
Semin Arthritis Rheum. 2000 Aug;30(1):70-7
pubmed: 10966214
J Dermatol. 2019 Mar;46(3):e108-e109
pubmed: 30192400
Swiss Med Wkly. 2012 May 31;142:w13590
pubmed: 22653747
Rheumatology (Oxford). 2021 Aug 2;60(8):e288-e289
pubmed: 33836074
Rev Rhum Mal Osteoartic. 1987 Mar;54(3):187-96
pubmed: 2954204
Eur J Immunol. 2012 Mar;42(3):710-5
pubmed: 22213227
Expert Rev Clin Immunol. 2018 Apr;14(4):275-283
pubmed: 29509041
Dermatology. 2021;237(5):673-697
pubmed: 32942279
Cytokine. 2014 Jul;68(1):1-8
pubmed: 24787050
Clin Exp Immunol. 2014 Oct;178(1):48-56
pubmed: 24903614
Dermatology. 2016;232(2):254-8
pubmed: 26919742
J Invest Dermatol. 2017 Nov;137(11):2389-2395
pubmed: 28652108
Br J Dermatol. 2018 Jan;178(1):e17-e18
pubmed: 28626985
Expert Rev Clin Pharmacol. 2017 Oct;10(10):1119-1128
pubmed: 28715916
Curr Med Chem. 2014;21(3):261-9
pubmed: 24164192
Arthritis Rheum. 2009 Dec;60(12):3642-50
pubmed: 19950258
Clin Rheumatol. 2013 Aug;32(8):1237-43
pubmed: 23604547
J Am Acad Dermatol. 2015 Jan;72(1):e42-4
pubmed: 25497954